Fulcrum Therapeutics (FULC) Metrics: History & Chart

Fulcrum Therapeutics, Inc.(FULC)

Biotechnology · Cambridge, MA

$3.69-0.02 (-0.54%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

9 employees

www.fulcrumtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexander C. Sapir

View full financials

Third-Party DCF Estimate (FMP)	$3.01
Price Gap vs Third-Party Estimate	-18.89%

7D Total Return	-0.27%
30D Total Return	-3.64%
YTD Total Return	-67.20%
1Y Total Return	-59.76%
3Y Total Return	-12.49%
5Y Total Return	-85.13%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-67.20%
2025	+140.64%
2024	-30.37%
2023	-7.28%
2022	-58.85%
2021	+51.07%
2020

CAGR TTM	-59.59%
CAGR 3Y	-4.35%
CAGR 5Y	-31.70%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

FULC Valuation Metrics

FULC Stock Price Metrics

FULC Dividend Metrics

FULC Growth Rate Metrics

FULC Discounted Cash Flow Metrics

FULC Returns By Period

FULC Yearly Returns

FULC Average Annual Returns By Period (CAGR)

FULC Revenue Metrics

FULC PE Ratio Metrics

FULC PS Ratio Metrics

FULC PB Ratio Metrics

FULC Price to Free Cash Flow Ratio Metrics

FULC Debt to Equity Ratio Metrics

FULC PEG Ratio Metrics

FULC FCF Yield

FULC Earnings Yield

FULC EBITDA Yield

FULC OCF Yield

FULC EV/EBIT Ratio Metrics

FULC EV/EBITDA Ratio Metrics

FULC EV/Assets Ratio Metrics

FULC EV/Sales Ratio Metrics

FULC Current Ratio Metrics

FULC Quick Ratio Metrics

FULC ROIC Metrics

FULC Return on Assets Metrics

FULC Return on Equity Metrics

FULC Net Profit Margin Metrics

FULC Gross Profit Margin Metrics

FULC Tax Rate Metrics

PS Ratio	5.93
PS Ratio Avg TTM	3.84
PS Ratio Avg 3Y	62.72
Current VS TTM Avg	+54.47%
Current VS 3Y Avg	-90.54%
Current VS 5Y Avg	-85.51%

PB Ratio	0.91
PB Ratio Avg TTM	1.94
PB Ratio Avg 3Y	1.68
Current VS TTM Avg	-52.97%
Current VS 3Y Avg	-45.71%
Current VS 5Y Avg	-45.14%

PFCF Ratio	62.74
PFCF Ratio Avg TTM	57.22
PFCF Ratio Avg 3Y	57.22
Current VS TTM Avg	+9.64%
Current VS 3Y Avg	+9.64%
Current VS 5Y Avg	+9.64%

Debt/Equity Ratio	0.02
Debt/Equity Ratio Avg TTM	0.02
Debt/Equity Ratio Avg 3Y	0.04
Current VS TTM Avg	-31.34%
Current VS 3Y Avg	-57.00%
Current VS 5Y Avg	-51.65%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.59%
FCF Yield Avg TTM	1.74%
FCF Yield Avg 3Y	1.74%
Current VS TTM Avg	-8.72%
Current VS 3Y Avg	-8.72%
Current VS 5Y Avg	-8.72%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.74
Ev/Assets Ratio Avg TTM	1.60
Ev/Assets Ratio Avg 3Y	1.39
Current VS TTM Avg	-53.66%
Current VS 3Y Avg	-46.92%
Current VS 5Y Avg	-44.65%

Ev/Sales Ratio	5.50
Ev/Sales Ratio Avg TTM	3.12
Ev/Sales Ratio Avg 3Y	58.16
Current VS TTM Avg	+76.06%
Current VS 3Y Avg	-90.54%
Current VS 5Y Avg	-81.62%

Current Ratio	31.35
Current Ratio Avg TTM	27.04
Current Ratio Avg 3Y	23.30
Current VS TTM Avg	+15.95%
Current VS 3Y Avg	+34.55%
Current VS 5Y Avg	+64.56%

Quick Ratio	31.35
Quick Ratio Avg TTM	27.04
Quick Ratio Avg 3Y	23.30
Current VS TTM Avg	+15.95%
Current VS 3Y Avg	+34.55%
Current VS 5Y Avg	+64.67%

ROIC	(27.62%)
ROIC Avg 3Y	(28.24%)
ROIC Avg 5Y	(35.27%)
Current VS 3Y Avg	+2.19%
Current VS 5Y Avg	+21.68%
Current VS 10Y Avg	+38.37%

ROA	(26.24%)
ROA Avg TTM	(7.15%)
ROA Avg 3Y	(7.90%)
Current VS TTM Avg	-266.91%
Current VS 3Y Avg	-231.96%
Current VS 5Y Avg	-207.60%

ROE	(27.36%)
ROE Avg TTM	(28.33%)
ROE Avg 3Y	(24.81%)
Current VS TTM Avg	+3.43%
Current VS 3Y Avg	-10.27%
Current VS 5Y Avg	+19.31%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	+100.00%

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	+100.00%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A